HROW

Dopo l'orario di chiusura: 36.08 -0.50 -1.37%

Harrow Inc (HROW)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché HROW Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Harrow Inc Stock (HROW) Company Profile

Healthcare (1069)

615.733.4731

1A BURTON HILLS BLVD, NASHVILLE, CA

Prossima data di guadagno

Ultimi documenti SEC

HROW's Discussions on Twitter

Compare HROW vs TAK, TEVA, HLN, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
HROW Harrow Inc	36.58	1.41B	272.30M	-5.14M	42.76M	-0.1635
TAK Takeda Pharmaceutical Co Adr	18.11	58.15B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.35	42.94B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.22	40.59B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	72.86	30.29B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	503.86	21.74B	3.17B	1.29B	1.01B	27.09

Harrow Inc Stock (HROW) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-07-11	Iniziato	Cantor Fitzgerald	Overweight
2025-06-12	Iniziato	BTIG Research	Buy
2025-06-10	Iniziato	William Blair	Outperform
2025-02-06	Iniziato	H.C. Wainwright	Buy
2024-12-04	Reiterato	B. Riley Securities	Buy
2024-04-11	Iniziato	Craig Hallum	Buy
2022-09-08	Ripresa	B. Riley Securities	Buy
2021-10-14	Ripresa	B. Riley Securities	Buy
2021-09-24	Iniziato	Aegis Capital	Buy
2021-07-02	Iniziato	Ladenburg Thalmann	Buy

Mostra tutto

Harrow Inc Borsa (HROW) Ultime notizie

Harrow Inc Azioni (HROW) Dati Finanziari

Harrow Inc (HROW)

Harrow Inc Stock (HROW) Company Profile

Compare HROW vs TAK, TEVA, HLN, ZTS, UTHR

Harrow Inc Stock (HROW) Upgrades & Downgrades

Harrow Inc Borsa (HROW) Ultime notizie

Harrow at Cantor healthcare conference: long view, bigger eye-care bet - Investing.com

HROW Initiates Coverage On Harrow -- Outperform Rating by Leerin - GuruFocus

Andrew R. Boll Assumes Principal Accounting Officer Role at Harrow (NASDAQ: HROW) - Kalkine Media

Andrew R. Boll named Harrow principal accounting officer as Randall E. Pollard departs - TradingView

Harrow, Inc. Announces Management Changes, Effective September 4, 2026 - marketscreener.com

Harrow Health Inc. (HROW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

HROW Q2 2026 Earnings: EPS Misses Estimates as Losses DeepenMid-Term Outlook - vinanet.vn

Harrow Health Inc. 8.625% Senior Notes due 2026 (HROWL) Key Financial Ratios – Valuation, Profitability & More - Value Research

Harrow Inc stock gains as analysts see strong revenue growth ahead - ad-hoc-news.de

Harrow Inc (HROW) Stock Up 5.6% and Still Undervalued -- GF Scor - GuruFocus

Harrow to Participate in Three Investor Conferences in September - GlobeNewswire

Harrow (HROW) Reported Positive IHEEZO Study Results In Intravitreal Injections - Sahm

Harrow (HROW) Quarterly Results: EPS Falls Short of Its Estimate in the Current Update; Price Move - vinanet.vn

Harrow (HROW) Quarterly Results: EPS Falls Short of Its Estimate in the Current Update; Price Move: Shares Move Lower 2.81% at the CloseEarnings Recovery Stocks - dars.gov.et

Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half - Sahm

Harrow (NASDAQ: HROW) CSO sells 11,250 shares in August option trade - Stock Titan

Harrow (HROW) Outlook: Ends Down by 2.64% at $40.95 for the Current Session; Next Session: Price Remains Between $38.90 Support and $43.00 Resistance on the DayShort Term Trading Ideas - vinanet.vn

What's Going On With Harrow Stock Friday?Harrow (NASDAQ:HROW) - Benzinga

Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections - Sahm

BTIG Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $63 - Moomoo

Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target - Yahoo Finance

In a 50-patient study, Harrow’s eye gel was linked to about 58% less injection discomfort - Stock Titan

Lake Street Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $60 - Moomoo

Harrow (HROW) Reaffirms 2026 Guidance, Is The Upside Already Priced In? - simplywall.st

Harrow And 2 Other Growth Stocks Insiders Are Betting On - simplywall.st

Harrow CSO Amir Shojaei sells $450,000 in company stock By Investing.com - Investing.com South Africa

Harrow CSO Amir Shojaei sells $450,000 in company stock - Investing.com

Rice Hall James & Associates LLC Takes Position in Harrow, Inc. $HROW - MarketBeat

Will Harrow’s (HROW) TYRVAYA Deal and Reaffirmed 2026 Guidance Redefine Its Dry Eye Strategy? - simplywall.st

Harrow (HROW) Q2 2026 Earnings Call Transcript - The Globe and Mail

Harrow (NASDAQ:HROW) Insider Amir Shojaei Sells 11,250 Shares - MarketBeat

Harrow Inc. (HROW) Slips 1.79% as Shares Test Key Support ZoneLast Point Resistance - vinanet.vn

HROW Q2 2026 Earnings: Wider Loss of $0.34 per Share Misses Estimates by 85.19%, but Stock Rises 2.98 - vinanet.vn

Wall Street Zen Upgrades Harrow (NASDAQ:HROW) to "Hold" - MarketBeat

HC Wainwright Issues Pessimistic Outlook for Harrow Earnings - marketbeat.com

Royce Micro-Cap Fund's Harrow Inc(HROW) Holding History - GuruFocus

Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine? - Yahoo Finance

Harrow: The Q2 Turnaround Is Enough For A Cautious Buy (NASDAQ:HROW) - Seeking Alpha

HC Wainwright Forecasts Harrow's Q4 Earnings (NASDAQ:HROW) - MarketBeat

Harrow (NASDAQ:HROW) Stock Rating Lowered by Zacks Research - MarketBeat

Earnings Update: Harrow, Inc. (NASDAQ:HROW) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st

Harrow announces product updates - Nashville Post

Harrow, Inc. (HROW) Stock Price, News, Quote & History - Yahoo! Finance Canada

Harrow (HROW) Adds New Eye Care Firepower With Product Launch And Acquisition - Yahoo Finance

Q2 2026 Harrow Inc Earnings Call Transcript - GuruFocus

A Look at Harrow Inc (HROW) After 3.2% Decline -- GF Value $44.5 - GuruFocus

HROW Looks 10.8% Undervalued on GF Value™ as Market Prices Growt - GuruFocus

HROW Reiterated by BTIG -- Price Target Maintained at $63 - GuruFocus

Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Dem - GuruFocus

Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Demand and Strategic Expansion ... - Yahoo Finance

Harrow (NASDAQ:HROW) Given Buy Rating at BTIG Research - MarketBeat

Harrow Inc Azioni (HROW) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a HROW